Enhancing Antibiotic Therapy Through Comprehensive Pharmacokinetic/pharmacodynamic Principles

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2025 Mar 12

PMID 40070375

Authors

Mohammad Sina Alikhani

Mohsen Nazari

Shima Hatamkhani

Affiliations

Soon will be listed here.

Abstract

Antibiotic therapy relies on understanding both pharmacokinetics (PK) and pharmacodynamics (PD), which respectively address drug absorption, distribution, and elimination, and the relationship between drug concentration and antimicrobial efficacy. This review synthesizes decades of research, drawing from studies, models, and clinical observations, to elucidate the temporal dynamics of antibiotic activity. We explore how these dynamics, including concentration-effect relationships and post antibiotic effects, inform the classification of antibiotics based on their PD profiles. Additionally, we discuss the pivotal role of PK/PD principles in determining optimal dosage regimens. By providing a comprehensive overview of PK/PD principles in antibiotic therapy, this review aims to enhance understanding and improve treatment outcomes in clinical practice.

References

Davidson R . In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections. Infect Drug Resist. 2019; 12:585-596. PMC: 6413744. DOI: 10.2147/IDR.S187226. View

Yoon S, Guk J, Lee S, Chae D, Kim J, Park K . Model-informed precision dosing in vancomycin treatment. Front Pharmacol. 2023; 14:1252757. PMC: 10593454. DOI: 10.3389/fphar.2023.1252757. View

Grant S, Hung D . Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response. Virulence. 2013; 4(4):273-83. PMC: 3710330. DOI: 10.4161/viru.23987. View

Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L . Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics. 2024; 16(3). PMC: 10975777. DOI: 10.3390/pharmaceutics16030332. View

Gibreel A, Taylor D . Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother. 2006; 58(2):243-55. DOI: 10.1093/jac/dkl210. View

Kembou-Ringert J, Readman J, Smith C, Breuer J, Standing J . Applications of the hollow-fibre infection model (HFIM) in viral infection studies. J Antimicrob Chemother. 2022; 78(1):8-20. PMC: 9780528. DOI: 10.1093/jac/dkac394. View

Xu K, Li D, Hu Z, Zhao C, Bai J, Du W . Vancomycin dosing in an obese patient with acute renal failure: A case report and review of literature. World J Clin Cases. 2022; 10(18):6218-6226. PMC: 9254177. DOI: 10.12998/wjcc.v10.i18.6218. View

Wicha S, Martson A, Nielsen E, Koch B, Friberg L, Alffenaar J . From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics. Clin Pharmacol Ther. 2021; 109(4):928-941. DOI: 10.1002/cpt.2202. View

Craig W . Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother. 1995; 7 Suppl 2:47-52. View

10.

Teo J, Fauzi N, Ho J, Tan S, Lee S, Lim T . Bactericidal Activities of Combination Antibiotic Therapies Against Carbapenem-Resistant With Different Carbapenemases and Sequence Types. Front Microbiol. 2021; 12:779988. PMC: 8713045. DOI: 10.3389/fmicb.2021.779988. View

11.

Horn K, Danziger L, Rodvold K, Glowacki R . Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA. Expert Opin Drug Metab Toxicol. 2017; 13(4):463-472. DOI: 10.1080/17425255.2017.1303481. View

12.

Anderson G . Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol. 2006; 2(6):947-60. DOI: 10.1517/17425255.2.6.947. View

13.

Onufrak N, Forrest A, Gonzalez D . Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther. 2016; 38(9):1930-47. PMC: 5039113. DOI: 10.1016/j.clinthera.2016.06.015. View

14.

Nazari M, Hemmati J, Asghari B . Comprehensive Analysis of Virulence Genes, Antibiotic Resistance, Biofilm Formation, and Sequence Types in Clinical Isolates of . Can J Infect Dis Med Microbiol. 2024; 2024:1403019. PMC: 11671628. DOI: 10.1155/cjid/1403019. View

15.

Nazari M, Taheri M, Nouri F, Bahmanzadeh M, Alikhani M . The antimicrobial and antibiofilm effects of gentamicin, imipenem, and fucoidan combinations against dual-species biofilms of Staphylococcus aureus and Acinetobacter baumannii isolated from diabetic foot ulcers. Ann Clin Microbiol Antimicrob. 2024; 23(1):101. PMC: 11568526. DOI: 10.1186/s12941-024-00760-w. View

16.

Tessier J, Scheld W . Principles of antimicrobial therapy. Handb Clin Neurol. 2010; 96:17-29. DOI: 10.1016/S0072-9752(09)96002-X. View

17.

Saravolatz L, Pawlak J, Martin H, Saravolatz S, Johnson L, Wold H . Postantibiotic effect and postantibiotic sub-MIC effect of LTX-109 and mupirocin on Staphylococcus aureus blood isolates. Lett Appl Microbiol. 2017; 65(5):410-413. DOI: 10.1111/lam.12792. View

18.

Tang Girdwood S, Dong M, Tang P, Stoneman E, Jones R, Yunger T . Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment. Antimicrob Agents Chemother. 2021; 66(1):e0142721. PMC: 8765235. DOI: 10.1128/AAC.01427-21. View

19.

Shi D, Mi G, Wang M, Webster T . In vitro and ex vivo systems at the forefront of infection modeling and drug discovery. Biomaterials. 2018; 198:228-249. PMC: 7172914. DOI: 10.1016/j.biomaterials.2018.10.030. View

20.

Palmer M, Andrews L, Abbey T, Dahlquist A, Wenzler E . The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A review. Front Pharmacol. 2022; 13:888079. PMC: 9359604. DOI: 10.3389/fphar.2022.888079. View